14th Annual Patient Recruitment and Retention Summit

23 - 24 February 2022 | Berlin

Patients have always been close to the clinical trials activities. But nowadays, with the overwhelming digitalisation era they are not just passive participants. They are the creators, designers and regulators throughout the whole clinical trial pipeline. If you do not think this applies for your organisation, then you should ask yourself: “Am I moving in the right direction?”

The 14th Annual Patient Recruitment and Retention Summit was designed to share the learning from the previous year, determine the relevant trends for efficient patient engagement in clinical trials, and predict the upcoming changes for the patient-centred clinical trials. Will be hybrid trials the solution for the accessibility? What to consider when going for an eConsent solution? Why do patients drop out of the trials? How to prevent this and save your budget? Let us answer these and many other questions to help you deliver outstanding performance when executing the clinical trial.

This patient recruitment and retention event is going to bring together senior-level representatives from top pharma companies. You will hear the best real-life case studies, benefit from remarkable networking opportunities and establish important business contacts. Enrich your knowledge, get the insights, discuss the innovations & challenges within the pharma industry. Register now to book your seat and become a part of something extraordinary!

Hottest topics that will be discussed this annual

  • The diversification of the patient recruitment approaches as a tool for the research underperformance prevention
  • What is the role of decentralised clinical trial methods in the process of patient enrolment?
  • The cooperation between companies and patient organisations as a way to facilitate patient engagement
  • How to develop and apply the relevant Patients Focused Medicine Development (PFMD) guides to encourage patients to stay in the trial?
  • Ways to communicate and aid your patients: Support programmes, counselling sessions and patient communities
  • Benefits and challenges of virtual clinical trials: Exploiting technology for effective global reach
  • Coping with the new normal: Lessons to learn and changes to do for patient engagement and retention

SUMMIT WILL HOST SPEAKERS FROM THE WORLD’S LEADING COMPANIES

Gunnar SCHROEFEL

Global Director Patient Advocacy

CASE STUDY DAY 2

Patient-Relevant Clinical Trials: Early Patient Involvement in the Design of Development Programmes

Active involvement of patient representatives early in the design phase of development programmes has become vital for the successful conduct of clinical trials. Patient panels discuss what patients expect from clinical trials, and what they need to gain a positive experience of participating in a trial. Patient boards help define patient-relevant outcomes by specifying what constitutes real benefit and value for patients. This session will reflect on the lessons learned to date from involving patient representatives in clinical trial design and explore the path forward.

• Comparing the perspectives of industry, research and patients
• What are best practices in involving patient representatives in clinical trial design?
• What are key challenges, and how are they overcome?
• Discussing the way to go to take patient involvement to the next level

Kimberley KALLSEN

Head of Patient & Site Journey, Global Clinical Development & Operations

CASE STUDY DAY 1

The Journey of Bringing the Voice of Patients and Sites into End-to-End Clinical Development

Bringing the voice of patients and sites into end-to-end clinical development will provide a good trial experience for trial participants, bring innovative treatments to patients faster by accelerating clinical development and ensure that new treatments fulfil patients’ needs and expectations.

• Examples for understanding the voice of patients and sites and bringing it into clinical development
• The importance of bringing all stakeholders together, including partnerships with patient organisations and healthcare professionals
• Challenges and future opportunities

Oleksandr GORBENKO

Global Patient Centricity Director

CASE STUDY DAY 1

Patient Engagement Strategies Across the Medicines Development Continuum: Ipsen Best Practices

In this presentation we will overview the best patient engagement strategies across the medicines development continuum and focus on our actions to improve patient recruitment and retention.

• Overview of best PE strategies across the medicines development continuum
• What we can do to improve patient recruitment and retention and some lessons learned over the COVID-19 pandemic
• Initiatives we have already implemented at Ipsen and in collaboration with our partners
• Further considerations

Orna SRUR KIDRON

Director, Decentralised Study Execution Strategy Lead

CASE STUDY DAY 1

Decentralised Clinical Trials (DCT) for Non-COVID-19 Reasons: Vision, Strategy and Implementation in Late Phase Studies

COVID-19 accelerated Teva to focus on the need to vision and implement a DCT strategic approach in our late phase studies, understanding that this may be the future for running clinical studies regardless “crisis” situations. The presentation is addressing what Teva gained since the COVID-19 pandemic appeared, what was our vision’s focus, our implementation strategy and efforts for leading a paradigm shift to the way we have conducted clinical trials so far.

• Background
• Building a streamline
• Identifying the stakeholders
• Continuous mitigation
• Implementation

Maarten BOOMSMA

Clinical Research Director

CASE STUDY DAY 2

Patient-Centred Research

Pharma trials are not all that accessible and attractive to patients. We are often confronted with this when recruitment is slow and investigators are desperate. What would make a protocol more attractive to a patient? And what putts them off? And how can we make it more attractive and easier to stay in the study for the whole treatment duration? The global pandemic has forced some changes in the conduct of clinical research. May be this was just that little push we needed. Let us jointly look at point for improvement for future trials.

• Pitt falls of clinical trial protocols
• Opportunities for clinical trial protocols
• The pandemic as a catalytic converter for more patient centred clinical trials Maarten

Enjoyed the event, it was very valuable. Good variety of topics and presentations – taking away lots of good ideas.

Associate Director, Patient Recruitment Programmes, Pfizer

We offer to world’s leading companies at our summit

Case Studies

Experience leaders will provide you with lessons learned.

Networking

The chance for market-leading business knowledge networking.

Discussions

All attendees will have a great opportunity to discuss a selection of topics in small groups with their peers.

New Ideas

We are partnering with experienced professionals to provide creative ideas, inspiration, and guidance.

Allan Lloyds Summit mission is to exceed expectations

We are committed to achieving new standards of excellence by providing conference formats that encourages interaction, networking and high class knowledge sharing. With experts, well-supported staff, motivated to deliver quality, Allan Lloyds vision is to be recognized as the global leader in providing high quality business conferences.

What we offer to world’s leading companies

  • Experience-based case studies
  • Round table discussions
  • Impeccable networking opportunities
  • Limited number of seats in the audience ensuring friendly atmosphere
  • No media or press presence

Sponsors

Few photos from our summits

Event programme

Fill your details in the form and we will
send you the whole brochure filled with all details

Your copy of the brochure is prepared.

Inside you will find

  • What keynote speakers will be taking part in the exclusive speaking panel
  • What Case Studies will be discussed by our senior corporate speakers
  • The minute by minute breakdown of the conference